Copyright
©The Author(s) 2015.
World J Clin Cases. Mar 16, 2015; 3(3): 210-220
Published online Mar 16, 2015. doi: 10.12998/wjcc.v3.i3.210
Published online Mar 16, 2015. doi: 10.12998/wjcc.v3.i3.210
Figure 2 Studies comparing outcomes of 24 vs 48 wk of therapy with pegylated interferon and ribavirin in patients with hepatitis C virus genotype 6.
aTreatment duration was tailored according to viral response at week 4: Patients with negative hepatitis C virus-RNA received 24 wk of treatment; the remainder received 48 wk. ns: Non-significant; nr: Not reported.
- Citation: Papastergiou V, Karatapanis S. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 2015; 3(3): 210-220
- URL: https://www.wjgnet.com/2307-8960/full/v3/i3/210.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v3.i3.210